
Tango Therapeutics (TNGX) Stock Forecast & Price Target
Tango Therapeutics (TNGX) Analyst Ratings
Bulls say
Tango Therapeutics is poised for future growth with upcoming catalysts in 2H26, including initial results for their MTA-cooperative PRMT5 inhibitors in lung and CNS cancers. The company's strong pipeline of precision oncology therapies, backed by positive clinical data for its lead asset vopimetostat, positions it well for success in the competitive KRAS and PRMT5 inhibitor market. With a discounted cash flow valuation of $11.6B and a terminal growth rate of 2%, Tango Therapeutics has a target price of $68 per share, indicating significant potential for growth. However, risks to achieving this target include negative clinical results and delays in advancing pipeline candidates.
Bears say
Tango Therapeutics is heavily reliant on the success of its PRMT5 inhibitors TNG462 and TNG456, which are still in early stages of development and may face R&D, regulatory, or commercial setbacks. Additionally, potential competition from already existing or emerging drug candidates targeting similar oncology indications could lower product sales for Tango and lead to dilutive financing transactions, which could have a negative impact on financials. Moreover, safety concerns with potential side effects from associated drugs may dampen physician enthusiasm for the usage of vopimetostat as a treatment option. Lastly, the highly competitive oncology market and the need for continuous financing further add to the company's long-term uncertainty and downside risks.
This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Tango Therapeutics (TNGX) Analyst Forecast & Price Prediction
Start investing in Tango Therapeutics (TNGX)
Order type
Buy in
Order amount
Est. shares
0 shares